Retatrutide (LY3437943) is Eli Lillys experimental triple-agonist drug that activates: GLP-1 (Glucagon-like peptide-1) reduces appetite and slows digestion GIP (Glucose-dependent insulinotropic peptide) enhances insulin sensitivity Glucagon receptor increases fat metabolism and energy expenditure In phase-2 trials, Retatrutide achieved up to 24% body-weight reduction rivaling or even surpassing bariatric surgery outcomes
People with Asperger's typically show advantages in verbal skills and tend to have higher IQs
Consistent with this, GHK-Cu produced roughly a 75% reduction in lipid peroxidation in tissue homogenate models at concentrations of 10-100 mM
Minoxidils vasodilation and hair cycle modulation complement GHK-Cus collagen synthesis and gene expression effects
The liver is especially relevant because it produces and uses large amounts of SAM, manages homocysteine through both remethylation and transsulfuration, synthesizes glutathione and carries out methylation- dependent reactions
For now, any decision to use GHK-Cu injections should be made with full awareness of the current knowledge and limitations